V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.465 USD -1%
Market Cap: 71.1m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

Intrinsic Value

VTGN's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VTGN stock under the Base Case scenario is 1.185 USD. Compared to the current market price of 2.465 USD, VistaGen Therapeutics Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VTGN Intrinsic Value
1.185 USD
Overvaluation 52%
Intrinsic Value
Price
V
Worst Case
Base Case
Best Case

Valuation History
VistaGen Therapeutics Inc

Compare VTGN to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about VTGN?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about VistaGen Therapeutics Inc

Provide an overview of the primary business activities
of VistaGen Therapeutics Inc.

What unique competitive advantages
does VistaGen Therapeutics Inc hold over its rivals?

What risks and challenges
does VistaGen Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in VistaGen Therapeutics Inc recently?

Summarize the latest earnings call
of VistaGen Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for VistaGen Therapeutics Inc.

Provide P/S
for VistaGen Therapeutics Inc.

Provide P/E
for VistaGen Therapeutics Inc.

Provide P/OCF
for VistaGen Therapeutics Inc.

Provide P/FCFE
for VistaGen Therapeutics Inc.

Provide P/B
for VistaGen Therapeutics Inc.

Provide EV/S
for VistaGen Therapeutics Inc.

Provide EV/GP
for VistaGen Therapeutics Inc.

Provide EV/EBITDA
for VistaGen Therapeutics Inc.

Provide EV/EBIT
for VistaGen Therapeutics Inc.

Provide EV/OCF
for VistaGen Therapeutics Inc.

Provide EV/FCFF
for VistaGen Therapeutics Inc.

Provide EV/IC
for VistaGen Therapeutics Inc.

Show me price targets
for VistaGen Therapeutics Inc made by professional analysts.

What are the Revenue projections
for VistaGen Therapeutics Inc?

How accurate were the past Revenue estimates
for VistaGen Therapeutics Inc?

What are the Net Income projections
for VistaGen Therapeutics Inc?

How accurate were the past Net Income estimates
for VistaGen Therapeutics Inc?

What are the EPS projections
for VistaGen Therapeutics Inc?

How accurate were the past EPS estimates
for VistaGen Therapeutics Inc?

What are the EBIT projections
for VistaGen Therapeutics Inc?

How accurate were the past EBIT estimates
for VistaGen Therapeutics Inc?

Compare the revenue forecasts
for VistaGen Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of VistaGen Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of VistaGen Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of VistaGen Therapeutics Inc compared to its peers.

Compare the P/E ratios
of VistaGen Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing VistaGen Therapeutics Inc with its peers.

Analyze the financial leverage
of VistaGen Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for VistaGen Therapeutics Inc.

Provide ROE
for VistaGen Therapeutics Inc.

Provide ROA
for VistaGen Therapeutics Inc.

Provide ROIC
for VistaGen Therapeutics Inc.

Provide ROCE
for VistaGen Therapeutics Inc.

Provide Gross Margin
for VistaGen Therapeutics Inc.

Provide Operating Margin
for VistaGen Therapeutics Inc.

Provide Net Margin
for VistaGen Therapeutics Inc.

Provide FCF Margin
for VistaGen Therapeutics Inc.

Show all solvency ratios
for VistaGen Therapeutics Inc.

Provide D/E Ratio
for VistaGen Therapeutics Inc.

Provide D/A Ratio
for VistaGen Therapeutics Inc.

Provide Interest Coverage Ratio
for VistaGen Therapeutics Inc.

Provide Altman Z-Score Ratio
for VistaGen Therapeutics Inc.

Provide Quick Ratio
for VistaGen Therapeutics Inc.

Provide Current Ratio
for VistaGen Therapeutics Inc.

Provide Cash Ratio
for VistaGen Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for VistaGen Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for VistaGen Therapeutics Inc?

What is the current Free Cash Flow
of VistaGen Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for VistaGen Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
VistaGen Therapeutics Inc

Current Assets 89.9m
Cash & Short-Term Investments 88.6m
Other Current Assets 1.4m
Non-Current Assets 2.4m
PP&E 1.9m
Other Non-Current Assets 477k
Current Liabilities 9.6m
Accounts Payable 1m
Accrued Liabilities 6.1m
Other Current Liabilities 2.5m
Non-Current Liabilities 1.6m
Other Non-Current Liabilities 1.6m
Efficiency

Free Cash Flow Analysis
VistaGen Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
VistaGen Therapeutics Inc

Revenue
698.3k USD
Operating Expenses
-53.5m USD
Operating Income
-52.8m USD
Other Expenses
5.5m USD
Net Income
-47.3m USD
Fundamental Scores

VTGN Profitability Score
Profitability Due Diligence

VistaGen Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

28/100
Profitability
Score

VistaGen Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.

VTGN Solvency Score
Solvency Due Diligence

VistaGen Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

VistaGen Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VTGN Price Targets Summary
VistaGen Therapeutics Inc

Wall Street analysts forecast VTGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VTGN is 13.26 USD with a low forecast of 12.12 USD and a high forecast of 15.75 USD.

Lowest
Price Target
12.12 USD
392% Upside
Average
Price Target
13.26 USD
438% Upside
Highest
Price Target
15.75 USD
539% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

VistaGen Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for VTGN is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

VTGN Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one VTGN stock?

The intrinsic value of one VTGN stock under the Base Case scenario is 1.185 USD.

Is VTGN stock undervalued or overvalued?

Compared to the current market price of 2.465 USD, VistaGen Therapeutics Inc is Overvalued by 52%.

Back to Top